Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Placebo (semaglutide)
- First Posted Date
- 2019-01-28
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 3533
- Registration Number
- NCT03819153
- Locations
- 🇺🇸
Rocky Mount Reg VA Med-DN, Aurora, Colorado, United States
🇨🇦Milestone Research, London, Ontario, Canada
🇨🇦LMC Research Inc. Ottawa, Nepean, Ontario, Canada
Research Study to Look at Fast-acting Insulin Aspart With the Insulin Pump System 'iLet™' in Adults With Type 1 Diabetes
Phase 2
Completed
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Device: iLet™
- First Posted Date
- 2019-01-25
- Last Posted Date
- 2020-06-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24
- Registration Number
- NCT03816761
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Boston, Massachusetts, United States
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
Phase 3
Active, not recruiting
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Placebo (semaglutide)
- First Posted Date
- 2019-01-22
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1500
- Registration Number
- NCT03811561
- Locations
- 🇸🇰
MEDIVASA, s.r.o., Diabetologicka ambulancia, Zilina, Slovakia
🇪🇸Hospital Vall d'Hebron, Barcelona, Spain
🇪🇸Hospital de Bellvitge, Hospitalet de Llobregat, Spain
STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity
Phase 3
Completed
- Conditions
- OverweightObesity
- Interventions
- Drug: Placebo (semaglutide)
- First Posted Date
- 2019-01-22
- Last Posted Date
- 2022-03-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 401
- Registration Number
- NCT03811574
- Locations
- 🇰🇷
Novo Nordisk Investigational Site, Yangsan, Korea, Republic of
An International Survey of the Occurrence of Cardiovascular Disease Among Patients With Type 2 Diabetes
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Other: No treatment given
- First Posted Date
- 2019-01-22
- Last Posted Date
- 2020-06-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 7548
- Registration Number
- NCT03811288
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Zonguldak, Turkey
A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4)
Phase 3
Active, not recruiting
- Conditions
- Growth Hormone Deficiency in Children
- Interventions
- First Posted Date
- 2019-01-22
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 200
- Registration Number
- NCT03811535
- Locations
- 🇸🇮
University Children's Hospital, Ljubljana, Slovenia
🇺🇸Univ of AL at Birmingham_BRM, Birmingham, Alabama, United States
🇺🇸Children's Hospital Los Angeles - Endocrinology, Los Angeles, California, United States
Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity
Phase 4
Completed
- Conditions
- Obesity
- Interventions
- Other: Weight Management Program (WMP)Drug: Medication for chronic weight management (Rx)
- First Posted Date
- 2019-01-10
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 200
- Registration Number
- NCT03799198
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Cleveland, Ohio, United States
A Study of People With Type 2 Diabetes Who Have Diseases That Affect the Heart and Blood Vessels. The Study Will Also Look at the Treatment of a Group of These People in Hospitals in Portugal
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Other: No treatment given
- First Posted Date
- 2019-01-09
- Last Posted Date
- 2020-11-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 730
- Registration Number
- NCT03797885
- Locations
- 🇵🇹
Novo Nordisk Investigational Site, Viseu, Portugal
A Research Study to Look at How Insulin 287 and Semaglutide Work in the Body of People With Type 2 Diabetes When Taken Alone or Together
Phase 1
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2018-12-28
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 30
- Registration Number
- NCT03789578
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
A Research Study of How NNC0174-0833 Behaves in Japanese and Caucasian Volunteers Who Are Normal Weight, Overweight or With Obesity
Phase 1
Completed
- Conditions
- ObesityOverweight
- Interventions
- Drug: Placebo (NNC0174-0833)
- First Posted Date
- 2018-12-26
- Last Posted Date
- 2019-06-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 66
- Registration Number
- NCT03787225
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Glendale, California, United States
© Copyright 2025. All Rights Reserved by MedPath